A new mathematical finding by an international research team provides the health care system with a more balanced approach to how patients are selected for treatment, which will consequently decrease wait times. Led by Western’s David Stanford, the tri-national team includes Peter Taylor from the University of Melbourne and Ilze Ziedins from the University of Auckland.
Recent scientific developments and methodological advances, coupled with rising research and development costs within the pharmaceutical industry have resulted in the need to change the way in which drug development is conducted. There is an ongoing effort to look for ways to accelerate drug development, reduce development costs, and address unmet needs while better identifying and addressing safety concerns. These developments have led to new demands and challenges in the way that statisticians contribute to drug development. In this discussion, we will look at some of these developments and challenges and their impact on the role of statisticians within the pharmaceutical industry. A brief description of the phases of pharmaceutical drug development will be presented and the role of the statistician within each phase will be highlighted. New and emerging opportunities for statisticians within the pharmaceutical industry and the evolving and changing role of the statistician will be discussed.